Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Precision medicine in non-small cell lung cancer: Current applications and future directions
Advances in biomarkers, targeted therapies, and immuno-oncology have transformed the
clinical management of patients with advanced NSCLC. For oncogene-driven tumors, there …
clinical management of patients with advanced NSCLC. For oncogene-driven tumors, there …
Recent progress in targeted therapy for non-small cell lung cancer
Y ** alterations
Background The hepatocyte growth factor receptor gene (MET) exon 14 skip** (METex14)
has recently been described a potential driver alteration in lung cancer targetable by …
has recently been described a potential driver alteration in lung cancer targetable by …
HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers
Cancer is a major cause of death worldwide. MET tyrosine kinase receptor [MET, c-MET,
hepatocyte growth factor (HGF) receptor] pathway activation is associated with the …
hepatocyte growth factor (HGF) receptor] pathway activation is associated with the …
Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges
Y ** events in lung cancer
KD Davies, A Lomboy, CA Lawrence… - Journal of Thoracic …, 2019 - Elsevier
Introduction Genomic variants that lead to MET proto-oncogenem receptor tyrosine kinase
(MET) exon 14 skip** represent a potential targetable molecular abnormality in NSCLC …
(MET) exon 14 skip** represent a potential targetable molecular abnormality in NSCLC …
[HTML][HTML] The race to target MET exon 14 skip** alterations in non-small cell lung cancer: the why, the how, the who, the unknown, and the inevitable
T Reungwetwattana, Y Liang, V Zhu, SHI Ou - Lung cancer, 2017 - Elsevier
A number of small molecule tyrosine kinase inhibitors (TKIs) have now been approved for
the treatment of non-small cell lung cancers (NSCLC), including those targeted against …
the treatment of non-small cell lung cancers (NSCLC), including those targeted against …